Although Pfizer has made some efforts to turn things around, they have been insufficient. Pfizer's poor performance since ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer ...

An experimental treatment by Pfizer and Arvinas delayed progression of breast cancer by more than three months compared to ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Pfizer (PFE) stock gains as Braftovi combo shows survival benefits in a late-stage trial for metastatic colorectal cancer ...

Simply meeting 5% growth estimates with no change in Pfizer's dirt-cheap valuation would produce over 12% annually -- boom, ...

Pfizer ( PFE 1.46%) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the ...

With billions of dollars being cut from public health programs worldwide, it’s only a matter of time before life-threatening viruses like COVID and HIV present a renewed threat here in Connecticut, ...

The "Addiction Disorders Drugs Market by Indication, Product Type, Route of Administration, Dosage Form, Distribution Channel, End User - Global Forecast to 2030" report has been added to ...

This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more ...